Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$102.19
+0.4%
$107.11
$89.67
$121.64
$177.77B0.765.49 million shs7.92 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$118.77
+0.3%
$131.99
$74.75
$142.00
$47.23B1.232.01 million shs6.07 million shs
Medtronic plc stock logo
MDT
Medtronic
$81.37
+1.0%
$82.60
$68.84
$91.00
$108.04B0.785.92 million shs11.41 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.03%-1.69%-3.52%-13.85%+0.19%
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-6.75%-6.22%-2.44%+1.29%
Medtronic plc stock logo
MDT
Medtronic
-0.02%-1.12%+0.56%-2.67%-1.68%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9543 of 5 stars
3.43.04.24.52.02.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.9593 of 5 stars
3.45.00.04.72.72.53.1
Medtronic plc stock logo
MDT
Medtronic
4.929 of 5 stars
3.13.03.34.13.22.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.70
Moderate Buy$120.6418.05% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.87
Moderate Buy$140.9418.66% Upside
Medtronic plc stock logo
MDT
Medtronic
2.25
Hold$93.0014.29% Upside

Current Analyst Ratings

Latest DXCM, ABT, and MDT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$121.00
5/30/2024
DexCom, Inc. stock logo
DXCM
DexCom
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$130.00
5/30/2024
Medtronic plc stock logo
MDT
Medtronic
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$83.00
5/24/2024
Medtronic plc stock logo
MDT
Medtronic
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$92.00
5/24/2024
Medtronic plc stock logo
MDT
Medtronic
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$102.00 ➝ $105.00
5/24/2024
Medtronic plc stock logo
MDT
Medtronic
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$75.00 ➝ $76.00
5/24/2024
Medtronic plc stock logo
MDT
Medtronic
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$90.00 ➝ $88.00
5/24/2024
Medtronic plc stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$128.00 ➝ $119.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.43$6.36 per share16.06$22.44 per share4.55
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B13.04$2.07 per share57.40$5.65 per share21.02
Medtronic plc stock logo
MDT
Medtronic
$32.36B3.34$7.20 per share11.30$37.97 per share2.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2131.8319.962.4613.96%20.18%10.60%7/18/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.5576.6353.262.9016.82%31.01%10.29%7/25/2024 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$2.7529.5913.932.3711.36%13.47%7.65%8/27/2024 (Estimated)

Latest DXCM, ABT, and MDT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2024Q4 24
Medtronic plc stock logo
MDT
Medtronic
$1.45$1.46+$0.01$2.43$8.44 billion$8.59 billion    
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million    
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.15%+12.31%68.54%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.763.39%+6.45%100.36%47 Years

Latest DXCM, ABT, and MDT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2024
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703.26%6/28/20246/28/20247/12/2024
3/7/2024
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.693.24%3/21/20243/22/20244/12/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.11
DexCom, Inc. stock logo
DXCM
DexCom
1.08
2.90
2.53
Medtronic plc stock logo
MDT
Medtronic
0.47
2.03
1.55

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Medtronic plc stock logo
MDT
Medtronic
82.06%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
DexCom, Inc. stock logo
DXCM
DexCom
0.30%
Medtronic plc stock logo
MDT
Medtronic
0.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600397.68 million396.49 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.33 billion1.32 billionOptionable

DXCM, ABT, and MDT Headlines

Recent News About These Companies

Medtronic (NYSE:MDT) Shares Down 0.4%
Is Medtronic Stock a Buy?
Medtronic (NYSE:MDT) Trading 0.7% Higher
Medtronic proves demand is deep for 30 years
Medtronic (NYSE:MDT) Shares Down 0.9%
The 3 Best MedTech Stocks to Buy Now: May 2024
The 3 Best MedTech Stocks to Buy Now: May 2024
Medtronic has a new Neurovascular president

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Medtronic logo

Medtronic

NYSE:MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.